Hilton Santa Fe Historic Plaza Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2017



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

PI3K Pathways in Immunology, Growth Disorders and Cancer (A6)


Organizer(s) Leon O. Murphy, Klaus Okkenhaug and Sabina C. Cosulich
January 19—23, 2017
Hilton Santa Fe Historic Plaza Hotel • Santa Fe, New Mexico USA
Discounted Abstract Deadline: Sep 21, 2016
Abstract Deadline: Oct 19, 2016
Scholarship Deadline: Sep 21, 2016
Discounted Registration Deadline: Nov 16, 2016

Sponsored by Bayer HealthCare Pharmaceuticals, Cell Signaling Technology, Inc., Incyte Corporation and Pfizer Inc.

Summary of Meeting:
The overall goal for this meeting is to bring together scientific leaders and trainees with a common interest in PI3Ks and relevant downstream physiological processes. It will address advances in basic molecular and cellular mechanisms that are regulated by PI3Ks, other PI kinases and, their cognate phosphatases; highlight new advances in the characterization of PI3K pathway alterations in genetic syndromes that affect growth and the immune and nervous systems; and provide an important update on the clinical development of PI3K pathway inhibitors, and implications for the burgeoning field of cancer immunotherapy. Whole exome sequencing studies have increasingly implicated PI3K signaling in diseases (immune, growth and neurological disorders) which may benefit from drugs currently in development for cancer and inflammation. This meeting will be an important forum for discussing approaches to treating these additional disorders.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Thursday, January 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Monday, January 23 with a closing plenary session and keynote address from 17:00 to 20:15, followed by a social hour and entertainment. We recommend return travel on Tuesday, January 24 in order to fully experience the meeting.

THURSDAY, JANUARY 19

4:00—8:00 PM
Arrival and Registration

Promenade
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Promenade

FRIDAY, JANUARY 20

7:00—8:00 AM
Breakfast

Pecos/Canyon
8:00—11:15 AM
PI3K Function and Physiology
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Lewis C. Cantley, Weill Cornell Medicine, USA

* Doreen A. Cantrell, University of Dundee, UK

Len R. Stephens, Babraham Institute, UK
Signaling via Class I PI3Ks

Bart Vanhaesebroeck, University College London, Cancer Institute, UK
Physiological Roles of PI3K Isoforms

Coffee Break

Matthias P. Wymann, University of Basel, Switzerland
Complexity in PI3K Signaling and Targeting

Jeffrey L. Kutok, Infinity Pharmaceuticals, USA
The PI3K-gamma Inhibitor, IPI-549, Increases Antitumor Immunity by Targeting Tumor-Associated Myeloid Cells and Overcomes Immune Checkpoint Blockade Resistance in Preclinical Tumor Models

John E. Burke, University of Victoria, Canada
Short Talk: Conformational Disturbance of PI3Kdelta Regulation by Primary Immunodeficiency Mutations in PIK3CD and PIK3R1

Kyle A. Edgar, Genentech, Inc., USA
Short Talk: The PI3K Inhibitor, Taselisib, has Enhanced Potency in PIK3CA Mutant Models Through a Unique Mechanism of Action

11:15 AM—5:00 PM
On Own for Lunch

11:15 AM—1:00 PM
Poster Setup

Mesa C
1:00—10:00 PM
Poster Viewing

Mesa C
4:30—5:00 PM
Coffee Available

Promenade
5:00—7:00 PM
PI3K Effectors
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Sabina C. Cosulich, AstraZeneca, UK

* Igor Vivanco, Institute of Cancer Research, UK

Brendan D. Manning, Harvard School of Public Health, USA
The TSC-Rheb-mTOR Circuit and Metabolic Control

David A. Fruman, University of California, Irvine, USA
The mTORC1/4E-BP/eIF4E Axis in B-Cell Activation and Transformation

John Blenis, Weill Cornell Medical College, USA
mTORC1/S6K1: Regulation of RNA Biogenesis, Protein Synthesis and Cell Metabolism

Ivan Yudushkin, Medical University of Vienna, Austria
Short Talk: Membrane Subpopulations of mTORC2 Display Distinct Sensitivity to PI3K

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pecos/Canyon
7:30—10:00 PM
Poster Session 1

Mesa C

SATURDAY, JANUARY 21

7:00—8:00 AM
Breakfast

Pecos/Canyon
8:00—11:15 AM
Phosphatases
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Len R. Stephens, Babraham Institute, UK

* Brendan D. Manning, Harvard School of Public Health, USA

Ramon Parsons, Icahn School of Medicine at Mount Sinai, USA
PTEN Upstream, Instream and Downstream

Lloyd Trotman, Cold Spring Harbor Laboratory, USA
PTEN Function and Loss of Function in Prostate Metastasis

Coffee Break

Christina Anne Mitchell, Monash University, Australia
New Roles for Inositol Polyphosphate Phosphatases

Doreen A. Cantrell, University of Dundee, UK
Phosphatidylinositol-3-Kinase Control of T Lymphocyte Differentiation: Dogma Versus Reality

Ana Clara Carrera, Centro Nacional Biotechnologia/CSIC, Spain
Short Talk: PI3K Depletion Induces Tumor Regression; E-Cadherin Downregulation Sensitizes PTEN-Mutant Tumors to PI3K-Beta Silencing

Sarah Elizabeth Conduit, Monash University, Australia
Short Talk: INPP5E Regulates Murine SHH Medulloblastoma

11:15 AM—2:30 PM
On Own for Lunch

11:15 AM—1:00 PM
Poster Setup

Mesa C
1:00—10:00 PM
Poster Viewing

Mesa C
2:30—4:30 PM
Workshop 1: PI3K, Metabolism and Stress Pathways

Mesa A-B
* Kyle A. Edgar, Genentech, Inc., USA

* John E. Burke, University of Victoria, Canada

Jack Flanagan, University of Auckland, New Zealand
Evidence of a New Mechanism for Achieving PI3K Inhibition with Small Molecules via an Effect on Membrane Binding

Thomas Leonard, Max F. Perutz Laboratories GmbH, Austria
PI(3,4,5)P3 Allosterically Activates Akt

Erika Ilagan, Harvard T.H. Chan School of Public Health, USA
The TSC-Rheb-mTORC1 Circuit is a Shared Effector of PI3K-Akt and Ras-Erk Signaling

Gina Lee, Weill Cornell Medicine, USA
mTORC1-S6K1 Regulation of SR Protein Kinase Links mRNA Biogenesis to De Novo Lipid Synthesis

Marie H. Solheim, Joslin Diabetes Center, Harvard Medical School, USA
Conserved p85alpha SH2 Domain Residues Play Differential Roles in p85alpha-IRS-1 Binding

Lukasz Pawel Magiera, University of Cambridge, UK
Pik3ca Gain-of-Function Mutation Restricted to Mesenchymal Cells Expressing Fibroblast Activation Protein-Alpha Causes Skeletal Overgrowth

4:30—5:00 PM
Coffee Available

Promenade
5:00—7:00 PM
Class II/III PI3Ks
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Jonathan M. Backer, Albert Einstein College of Medicine, USA

Volker Haucke, Leibniz Institut für Molekulare Pharmakologie, Germany
Phosphoinositide Conversion in the Endolysosomal System

Leon O. Murphy, Third Rock Ventures, USA
Role of VPS34 in Cancer Growth and Autophagy

Emilio Hirsch, Fondazione per la Ricerca Biomedica – ONLUS, Italy
Class II PI3K in Mitosis

Wei-Xing Zong, Rutgers University, USA
Short Talk: PI3-Kinase p110beta Regulates Cell Metabolism and Oncogenesis by Promoting Endocytic Turnover of Nutrient Transporters

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pecos/Canyon
7:30—10:00 PM
Poster Session 2

Mesa C

SUNDAY, JANUARY 22

7:00—8:00 AM
Breakfast

Pecos/Canyon
8:00—11:15 AM
Signaling from Non-Canonical PI Kinases
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Bart Vanhaesebroeck, University College London, Cancer Institute, UK

* Klaus Okkenhaug, Babraham Institute, UK

Brooke M. Emerling, Sanford Burnham Prebys Medical Discovery Institute, USA
PI5P4Ks and Cancer Metabolism

Pietro V. De Camilli, Yale University School of Medicine, USA
Phosphoinositide Dynamics at the Plasma Membrane

Coffee Break

Nullin Divecha, University of Southampton, UK
Phosphoinositides and Nuclear Signaling

Tamas Balla, NICHD, National Institutes of Health, USA
Phosphatidylinositol 4-Kinases: Keys to Lipid Transport and Metabolism

Miguel Murillo, Institute of Cancer Research, UK
Short Talk: Disrupting RAS-PI3K Interaction Promotes EFGR-Induced Tumor Regression Abrogating RAC1-Mediated Positive Feedback Loop

Sreenivasa R. Chinni, Wayne State University, USA
Short Talk: PI4KIII Alpha-CXCR4 Axis Cross-Talk in Prostate Cancer Promotes Cell Invasion

11:15 AM—5:00 PM
On Own for Lunch

11:15 AM—1:00 PM
Poster Setup

Mesa C
1:00—10:00 PM
Poster Viewing

Mesa C
3:00—4:30 PM
Panel: Career Development
This panel will include an established PI, a new PI, an industry scientist and will facilitate an interactive session on early career development for scientists.

Mesa A-B
* Leon O. Murphy, Third Rock Ventures, USA

Brooke M. Emerling, Sanford Burnham Prebys Medical Discovery Institute, USA

Igor Vivanco, Institute of Cancer Research, UK

Sue Menon, Novartis, USA

Pamela L. Schwartzberg, NHGRI, National Institutes of Health, USA

4:30—5:00 PM
Coffee Available

Promenade
5:00—7:00 PM
Overgrowth Syndromes
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Edith M. Hessel, GlaxoSmithKline, UK

* Leon O. Murphy, Third Rock Ventures, USA

Robert K. Semple, University of Cambridge, UK
Human Disorders of Growth due to Type 1A PI3K Mutations

Kathleen Millen, Seattle Children's Research Institute, USA
The Role of PIK3CA in Megalencephaly and Epilepsy

Cameron C. Trenor III, Boston Children's Hospital, USA
Overgrowth and Vascular Anomalies: PIK3CA Heterogeneity and Sirolimus Responses

Ghayda Mirzaa, Seattle Children's Hospital, USA
Short Talk: Mosaic and Constitutional Mutations of the PI3K-AKT-MTOR Pathway are Associated with a Wide Spectrum of Developmental Brain Disorders from Focal Cortical Dysplasia to Diffuse Megalencephaly with Autism

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pecos/Canyon
7:30—10:00 PM
Poster Session 3

Mesa C

MONDAY, JANUARY 23

7:00—8:00 AM
Breakfast

Pecos/Canyon
8:00—11:15 AM
PI3K in Immunity and Infection
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* David A. Fruman, University of California, Irvine, USA

Klaus Okkenhaug, Babraham Institute, UK
Class I PI3K Isoforms and Mutants in Immunity, Infection and Cancer

Pamela L. Schwartzberg, NHGRI, National Institutes of Health, USA
PIK3CD and Immunodeficiency

Coffee Break

Laurence A. Turka, Massachusetts General Hospital, USA
PI3K Signaling and Metabolism in Regulatory T Cells

Edith M. Hessel, GlaxoSmithKline, UK
Developing PI3K Inhibitors for COPD and Respiratory Disease

Christoph Burkhart, Novartis Institutes for BioMedical Research, Switzerland
Short Talk: The PI3K-Delta Inhibitor CDZ173 (leniolisib) Rescues the Immune Cell Defects and Improves the Clinical Course in Patients with Activated PI3K-delta Syndrome (APDS)

Carrie L. Lucas, Yale University, USA
Short Talk: Human Immune Dysregulation Caused by Mutations in the Gene Encoding the p110g PI3K Subunit

11:15 AM—2:30 PM
On Own for Lunch

2:30—4:30 PM
Workshop 2: PI3K in Immune Disorders and Immuno-Oncology

Mesa A-B
* Carrie L. Lucas, Yale University, USA

* Christoph Burkhart, Novartis Institutes for BioMedical Research, Switzerland

Honyin Chiu, University of California, Irvine, USA
A Novel Role for the 4E-BP/eIF4E Axis in B Cell Antibody Class Switching

Elissa K. Deenick, Garvan Institute of Medical Research, Australia
Over Activation of PI3K Causes Defects In B-Cell Development and Differentiation

Anne-Katrien Stark, Babraham Institute, UK
PI3Kdelta Hyper-Activation Results in Increased Susceptibility to S. Pneumoniae Airway Infection

Maria Gonzalez-Nunez, Queen Mary University of London, UK
The Role of p110delta PI3K Signaling in NOD2-Mediated Gastrointestinal Immunity and Inflammation

Aimé Cézaire Adiko, Center for Research on Inflammation/ Paris University, France
Opposite Effects of two PI3K Gamma Regulatory Subunits in Dendritic Cells

Anita Chandra, Babraham Institute, UK
B Cell Function and Development in the Context of PI3Kdelta Hyper-Activation

Sarah H. Ross, University of Dundee, Scotland
Understanding the Regulation of PI(3,4,5)P3 Levels in Effector Cytotoxic T Lymphocytes

4:30—5:00 PM
Coffee Available

Promenade
5:00—6:30 PM
PI3K and Oncology
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* John Blenis, Weill Cornell Medical College, USA

Mika Derynck, Genentech, Inc., USA
Clinical Drug Development of PI3K Pathway Inhibitors in Solid Tumors: Threading the Needle for a Therapeutic Index

Sabina C. Cosulich, AstraZeneca, UK
Clinical Development of mTOR Inhibitors

Jennifer R. Brown, Dana-Farber Cancer Institute, USA
Clinical Development of PI3K Inhibitors for CLL

6:30—7:15 PM
Closing Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Leon O. Murphy, Third Rock Ventures, USA

Lewis C. Cantley, Weill Cornell Medicine, USA
PI3K and Cancer Metabolism

7:15—7:30 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
8:15—9:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Promenade/Mesa Ballroom
8:15—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Mesa Ballroom

TUESDAY, JANUARY 24

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Bayer HealthCare Pharmaceuticals Cell Signaling Technology, Inc.
Incyte Corporation Pfizer Inc.

We gratefully acknowledge additional support for this conference from:

Bethyl Laboratories, Inc.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



AstraZeneca


Cell Signaling Technology, Inc.


Genentech, Inc.


Novartis Institutes for BioMedical Research


Third Rock Ventures


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676